---
title: "QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References"
description: "Reference list for the formulary evidence report on QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations. 76 cited documents."
canonical: "https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References

<a id="references"></a>

## 5 References

1. [Abtahi-Naeini et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12742332/)
2. [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)
3. [Allemang-Trivalle et al. (2026)](https://www.nature.com/articles/s41598-026-36295-7)
4. [Badia et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31930696/)
5. [Balakrishnan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22675002/)
6. [Bonilla-Velez et al. (2025)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2831727)
7. [Cai et al. (2023)](https://www.jaad.org/article/S0190-9622%2819%2930165-3/fulltext)
8. [Çalışkan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30133999/)
9. [Canaud et al. (2021)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01929-8)
10. [Cheng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5647489/)
11. [ClinicalTrials.gov NCT05050149](https://clinicaltrials.gov/study/NCT05050149?aggFilters=status%3Acom&cond=Lymphatic+Abnormalities&rank=3&tab=results)
12. [Cui et al. (2026)](https://www.dovepress.com/topical-sirolimus-gel-for-the-treatment-of-superficial-microcystic-lym-peer-reviewed-fulltext-article-CCID)
13. [Dodds et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31957126/)
14. [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=829421)
15. [Gallagher et al. (2022)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02336-3)
16. [García-Montero et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28557723/)
17. [García-Montero et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30296533/)
18. [Ghaffarpour et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30556934/)
19. [Ghaffarpour et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36223836/)
20. [Goldenberg et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12237419/)
21. [Gu and Sebaratnam (2024)](https://pubmed.ncbi.nlm.nih.gov/37717734/)
22. [Hollman et al. (2026)](https://journals.sagepub.com/doi/10.1177/12034754251386785)
23. [Huerta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914511/)
24. [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)
25. [Ivars and Redondo (2017)](https://pubmed.ncbi.nlm.nih.gov/27784048/)
26. [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)
27. [Kalwani and Rockson (2021)](https://pubmed.ncbi.nlm.nih.gov/33540133/)
28. [Kamireddy et al. (2026)](https://www.ovid.com/jnls/jova/fulltext/10.1097/jova.0000000000000133~microcystic-and-macrocystic-lymphatic-malformations-distinct)
29. [Kinoshita et al. (2026)](https://link.springer.com/article/10.1007/s11604-025-01932-0)
30. [Kirkham et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5938064/)
31. [Kitchloo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39213789/)
32. [Lapa and Sandre (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13076952/)
33. [Le Sage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29790593/)
34. [Leboulanger et al. (2023)](https://link.springer.com/article/10.1186/s13023-022-02608-y)
35. [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)
36. [Mäkinen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34166072/)
37. [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)
38. [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)
39. [Palvella Therapeutics Breakthrough Therapy designation announcement (2023)](https://www.globenewswire.com/news-release/2023/11/16/2781752/0/en/Palvella-Therapeutics-Announces-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-M.html)
40. [Palvella Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-ex99_2.htm)
41. [Palvella Therapeutics corporate update and 2026 outlook announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-provides-corporate-update-and-2026-outlook/)
42. [Palvella Therapeutics expanded access policy](https://www.palvellatx.com/expanded-access-policy)
43. [Palvella Therapeutics first NDA module submission announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-submits-first-module-rolling-new-drug)
44. [Palvella Therapeutics first quarter 2026 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-first-quarter-2026-financial/)
45. [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)
46. [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)
47. [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)
48. [Palvella Therapeutics full-year 2025 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-full-year-2025-financial-results/)
49. [Palvella Therapeutics investor relations website](https://ir.palvellatx.com/)
50. [Palvella Therapeutics NDA acceptance and Priority Review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-announces-fda-acceptance-and-priority-review-qtorintm)
51. [Palvella Therapeutics NDA submission completion announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-completes-rolling-submission-new-drug)
52. [Palvella Therapeutics phase 2 publication announcement (2025)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-publication-results-phase-2)
53. [Palvella Therapeutics phase 2 topline results announcement (2023)](https://www.biospace.com/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations)
54. [Palvella Therapeutics pipeline update announcement (2023)](https://www.globenewswire.com/news-release/2023/02/21/2611988/0/en/palvella-therapeutics-announces-pipeline-update-on-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-for-serious-rare-genetic-skin-diseases-with-no-fda-approved-therapies.html)
55. [Palvella Therapeutics pipeline web page](https://palvellatx.com/pipeline/)
56. [Palvella Therapeutics presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-ex99_1.htm)
57. [Palvella Therapeutics rolling review announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/fda-grants-rolling-review-palvellas-qtorintm-rapamycin-nda)
58. [Palvella Therapeutics second quarter 2026 results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-reports-second-quarter-2026-financial)
59. [Palvella Therapeutics SELVA and TOIVA data announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-presents-new-selva-and-toiva-data-2026/)
60. [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)
61. [Palvella Therapeutics website](https://www.palvellatx.com/)
62. [Palvella Therapeutics World Congress of Pediatric Dermatology announcement (2025)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-qtorintm-rapamycin-39-anhydrous/)
63. [PeDRA (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Fit-For-Purpose-Martini.pdf)
64. [Saibene et al. (2023)](https://link.springer.com/article/10.1007/s00405-023-07991-1)
65. [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)
66. [Seront et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04151-y)
67. [Teng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35852876/)
68. [Teng et al. (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Novel-Endpoint-Teng.pdf)
69. [Teng et al. (2025)](https://www.jidonline.org/article/S0022-202X%2825%2900283-0/fulltext)
70. [Treat (2026)](https://www.palvellatx.com/wp-content/uploads/2026/05/ISSVA-QTORIN-Rapamycin-Presentation-by-Dr-Jim-Treat.pdf)
71. [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)
72. [Vandersteen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39984430/)
73. [Wiegand et al. (2009)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/410557)
74. [Xu et al. (2026)](https://www.dovepress.com/short-term-efficacy-and-safety-of-topical-sirolimus-gel-in-pediatric-s-peer-reviewed-fulltext-article-VHRM)
75. [Yonekura et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36044195/)
76. [Zenner et al. (2019)](https://insight.jci.org/articles/view/129884)

## Related pages
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations.md)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic information and modeling report](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: prevalence by geography](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses.md)
